Short-term presurgical treatment for all? by Dowsett, Mitch et al.
Introduction
There are two types of presurgical treatment of primary breast
cancer [1]: one in which clinical downstaging is the goal and
end-point, and one that is shorter in duration and does not
involve delay to normal surgical scheduling. The latter, so-
called ‘window of opportunity’ studies of about 2 weeks’
duration, are the focus of this article.
Short-term presurgical studies require biomarkers for their
assessments of pharmacological effectiveness. These same
biomarkers may be intermediate markers of eventual clinical
efficacy if the treatment were to be continued. Given that
increases or decreases in tumour growth require changes in
the balance between cell multiplication and loss, markers of
the processes have become important biomarkers for
presurgical treatment. There is now substantial data to
support their validity as markers of therapeutic benefit for
both chemotherapy and endocrine therapy.
Proliferation
The most widely used measurement of proliferation is
immunohistochemical assessment of Ki67. We recently
reviewed its biology and importance in breast cancer [2].
Other measures of proliferation used in breast cancer include
flow cytometric assessment of S-phase, mitotic index (a
component of pathologic grade) and thymidylate synthase.
None of these markers provides a measure of the proliferative
rate because they are static, snapshot-in-time measures. The
incorporation of bromodeoxyuridine (BrDU) allows a
measurement of proliferative rate, but this is a rarely
performed measurement because of its complexity and some
safety concerns. The pre-eminence of Ki67 is largely because
of the relative simplicity of its measurement. The most widely
used antibody of recent years has been MIB1.
Cell death
Cell death in relation to medical therapy appears largely to be
as a result of apoptotic programmed cell death. This may be
measured by morphologic criteria using standard
microscopic techniques, but it is more often measured in vivo
by application of the TUNEL (TdT-mediated dUTP-biotin nick
end labeling) methodology that links biotinylated nucleotides
to the enormous number of DNA strand ends created during
late-stage apoptosis. The immunohistochemical staining of
components of the execution machinery of apoptosis, such
as activated caspase 3, have been assessed as surrogates
for apoptosis itself with variable success [3,4]. The role of
necrosis in the response to treatment of human breast cancer
appears to be limited, although this probably accounts for a
significant proportion of the tumour dynamics seen in rapidly
regressing xenograft models. Autophagy may also contribute
to cell death in response to some treatments, but this
process also acts as a survival mechanism during the early
response to metabolic stress [5], making it difficult to assess
the importance of autophagy to tumour cell loss.
Assay precision
For widespread applicability it is necessary to have well
defined assay precision. We assessed the precision of
making measurements of Ki67 and apoptosis by taking two
cores with 14-gauge needles from the same tumour at the
same time without intervening treatment [6]. The mean error
was 33% (standard deviation [SD] 16%) for Ki67 and 38%
(SD 22%) for apoptosis. These data provided statistical
power for our early studies in which these markers were
primary end-points. Capturing the data from the placebo arm
of some of those studies subsequently allowed us to expand
the precision data. In a similar study using fine needle
aspirates rather than cores, it became clear that the larger
proportional but smaller absolute differences seen at low
values of the markers created an error relationship that was
not completely linear [7].
Relationship between proliferation and
apoptosis
There is a significant direct correlation between Ki67 levels
and apoptosis in breast cancer [8]. This probably explains the
counterintuitive observation that when apoptosis is assessed
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as a univariate it is associated with poor prognosis, but when
both proliferation and apoptosis are included in the model
apoptosis no longer exhibits a significant association with
clinical outcome [8]. Assessment of apoptosis as well as
proliferation does not appear to improve prediction of
outcome above proliferation alone. However, its assessment
as a changing parameter in relation to treatment response is
of substantial importance, particularly in terms of
chemotherapy.
Chemotherapy
Higher proliferation at baseline is among several biomarkers
that exhibit an inverse association between response to
neoadjuvant chemotherapy and long-term outcome (for a
review see [2]). This may be confounding when extrapolating
biomarker data in the neoadjuvant setting to clinical outcome
in the adjuvant setting.
Apoptosis can be seen to increase significantly in most, but
not all, patients during the first 24 hours of chemotherapy [9].
Initial data suggested that this might predict benefit from
neoadjuvant chemotherapy [10], but further work indicated
that the relationship is poor at best [11]. This may be due to
variable pharmacokinetics and pharmacodynamics over this
early period. Proliferation is also reduced modestly in this
early period, but the changes are not closely related to
clinical response. Assessments at 21 days have been more
consistent in indicating a relationship between decreased
proliferation and eventual clinical response to chemotherapy
[2,7,10].
We recently assessed the relationship of Ki67 pretreatment
and at surgery with recurrence-free survival (RFS) in patients
receiving anthracyclin-based chemotherapy [12]. Before
treatment, we found the expected relationship between high
Ki67 and poor outcome (P = 0.0007). In the excision
specimen the relationship was stronger (P < 0.0001); median
RFS was about 18 months for patients with Ki67 in the
highest tertile, as compared with more than 7 years for the
other two tertiles. The data suggest that although patients
with high proliferation pretreatment have a good chance of a
pathological complete remission, if they do not achieve this
then their outcome is likely to be very poor.
Despite these positive and potentially clinically helpful data,
for short-term presurgical studies of chemotherapy to
become widely used, more data on long-term significance
after 21 days or less are needed along with evidence that this
would usefully alter clinical practice.
Endocrine therapy
Several studies have assessed changes in proliferation
and/or apoptosis as biological efficacy measures of endo-
crine treatments. The neoadjuvant IMPACT (Immediate
Preoperative Anastrozole Tamoxifen or Combined with
Tamoxifen) trial randomly assigned postmenopausal patients
with primary breast cancer to anastrozole, tamoxifen, or the
combination of anastrozole and tamoxifen [13,14]. This
randomization was identical to that in the ATAC (Arimidex,
Tamoxifen Alone or Combination) adjuvant trial [15]. The
reduction in Ki67 with anastrozole was also greater than that
with tamoxifen or the combination both at 2 weeks and at
12 weeks, thus predicting the RFS differences in ATAC. This
provokes the question of whether ATAC would have
persisted with the combination arm had data from IMPACT
been available before its initiation. Exclusion of this arm would
have incurred major savings at many levels. Our recent report
that anastrozole plus gefitinib was no more effective than
anastrozole alone in suppressing Ki67 in the presurgical
setting is discouraging for the development of that combina-
tion for early breast cancer treatment [16].
Unexpected decreases in apoptosis have been observed
after treatment with aromatase inhibitors and tamoxifen
[14,17]. These may be due to the close relationship between
apoptosis and proliferation discussed above.
Unlike Ki67, clinical response in IMPACT did not exhibit the
differences between the three treatment arms that were seen
in RFS in ATAC. This may be due to the imprecision in
measuring clinical response but there may be other, more
fundamental reasons. After 2 weeks of anastrozole or
tamoxifen, 52 out of 56 and 46 out of 54 patients,
respectively, exhibited decreased Ki67. Thus, almost all
patients appeared to have some antiproliferative benefit, but
this varied markedly between patients. In particular, some
patients with high Ki67 levels before treatment exhibited a
modest fall by 2 weeks. Such falls would not be expected to
be associated with the regression of a rapidly growing
tumour, but if considered in the adjuvant setting such
changes might be associated with improved RFS. Thus, it is
rational that there might be a closer relationship between
change in proliferation in the neoadjuvant setting and benefit
from adjuvant therapy than from response in the neoadjuvant
setting itself.
Given that baseline Ki67 is prognostic and the evidence
above suggests that a 2-week change in Ki67 is predictive of
benefit, it is rational that the absolute value of Ki67 at
2 weeks might integrate the intrinsic prognostic importance
of Ki67 at baseline and the predictive value of change; it
would therefore be expected to relate more closely to long-
term outcome with a given treatment than baseline Ki67. This
hypothesis was confirmed in the IMPACT trial, where the
2-week value of Ki67 had a better association with RFS than
the pretreatment value [18]. To translate these findings into
routine clinical practice requires the relationship between
2-week Ki67 and RFS to be characterized more fully. This
should be accomplished by the POETIC (Peri-Operative
Endocrine Therapy for Individualized Care) trial, a large
clinical study of aromatase inhibitor therapy, or no such
therapy, before surgical resection, which will also provideAvailable online http://breast-cancer-research.com/content/9/S2/S13
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tissue to allow detailed study of the molecular changes
resulting from oestrogen deprivation; this may allow improved
insight into the mechanisms that underpin benefit from
endocrine therapy.
Conclusion
Treatment-induced, short-term presurgical changes in
proliferation and apoptosis have an established role in
evaluation of new drugs and show promise for prediction of
benefit from existing treatments of primary breast cancer.
Research is ongoing to determine whether they may merit
assessment in most patients.
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